In vivo pharmacokinetics of calreticulin S-domain, an inhibitor of the classical complement pathway

Inhibition of the complement system is potentially therapeutic in diseases where uncontrolled or overshooting complement activation plays a significant role in the pathogenesis of the disorder. Calreticulin (CRT) is a multifunctional protein whose cell-surface form (ectocalreticulin) is reported to...

Full description

Saved in:
Bibliographic Details
Published in:International immunopharmacology 2002-03, Vol.2 (4), p.415-422
Main Authors: Lynch, Nicholas J., Schneider, Heiko, Sim, Robert B., Bickel, Ulrich, Schwaeble, Wilhelm J.
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Blood-Brain Barrier
Calreticulin
Calreticulin - chemistry
Calreticulin - pharmacokinetics
Calreticulin - pharmacology
Complement
Complement C1 Inactivator Proteins - chemistry
Complement C1 Inactivator Proteins - pharmacokinetics
Complement C1 Inactivator Proteins - pharmacology
complement component C1q
Complement Pathway, Classical - drug effects
CUB-domain
ectocalreticulin
Half-Life
Immunomodulators
Inhibitor
Iodine Radioisotopes
Male
Medical sciences
Pharmacokinetics
Pharmacology. Drug treatments
Protein Structure, Tertiary
Rats
Rats, Sprague-Dawley
Tissue Distribution
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inhibition of the complement system is potentially therapeutic in diseases where uncontrolled or overshooting complement activation plays a significant role in the pathogenesis of the disorder. Calreticulin (CRT) is a multifunctional protein whose cell-surface form (ectocalreticulin) is reported to be a C1q receptor. A 124-residue domain within CRT, the S-domain, binds to C1q, prevents the formation of C1 and so inhibits activation of the classical pathway. To assess the usefulness of CRT S-domain as a complement inhibitor, recombinant S-domain was expressed, radiolabeled, and the fate of the radiolabeled peptide followed in vivo. In rats, CRT-S-domain shows a half-life of 1.21±0.34 and 40.5±2.7 min in the distribution and elimination phases from plasma, respectively. The peptide remains largely intact, and is cleared from the circulation by the kidneys, where it accumulates in the proximal convoluted tubules, but is not excreted. Much smaller amounts of the peptide accumulate in other tissues, and essentially none crosses the blood–brain barrier.
ISSN:1567-5769
1878-1705
DOI:10.1016/S1567-5769(01)00165-5